Literature DB >> 21472645

The role of Chinese medicine in the treatment of chronic diseases in China.

Miao Jiang1, Chi Zhang, Hongxin Cao, Kelvin Chan, Aiping Lu.   

Abstract

Chinese medicine (CM) has a long history of experience and proven successful treatment for chronic diseases and has also played an important role in the provision of health care in China. Patients with chronic diseases are happy to accept CM and physicians are willing to use CM to relieve patients suffering from chronic illnesses. The Chinese health authorities encourage CM development to meet the requirements for the treatment of chronic diseases. CM products are an essential part of medications that have a predominant role in the prevention and treatment of chronic diseases in China. A large number of CM clinical studies, including a substantial number of available randomized controlled trials and systematic reviews, have shown that CM is effective and safe in the treatment of chronic diseases. Although the efficacies of some evaluated CM therapies remain uncertain, it is worth assessing them by using CM pattern (Zheng or syndrome) differentiation to verify treatment outcomes. CM is considered to have a better safety profile compared to pharmaceutical chemicals, but inappropriate applications of CM also makes the safety issues a hot discussed subject. As a medical system, CM should be able to provide worldwide contribution for the patients who are suffering from chronic diseases. The application of CM pattern classification in diagnosis with corresponding prescribed treatment using herbal formulae in the relief of chronic diseases can be linked with modern biomedical parameters (biomarkers) as treatment outcomes. These outcome parameters, together with the patients' reported quality of life assessment, can provide innovative approaches for evidence-based estimation of the efficacy of CM treatment in chronic diseases. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21472645     DOI: 10.1055/s-0030-1270983

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  25 in total

1.  An innovative method to accommodate Chinese medicine pattern diagnosis within the framework of evidence-based medical research.

Authors:  Christine Berle; Deirdre Cobbin; Narelle Smith; Christopher Zaslawski
Journal:  Chin J Integr Med       Date:  2011-11-06       Impact factor: 1.978

2.  Jabuticaba peel extract modulates adipocyte and osteoblast differentiation of MSCs from healthy and osteoporotic rats.

Authors:  Alann Thaffarell Portilho Souza; Gileade Pereira Freitas; Helena Bacha Lopes; Gabriela Guaraldo Campos Totoli; Adriana Gadioli Tarone; Mario Roberto Marostica-Junior; Adalberto Luiz Rosa; Marcio Mateus Beloti
Journal:  J Bone Miner Metab       Date:  2020-09-05       Impact factor: 2.626

3.  Preferences for Primary Healthcare Services Among Older Adults with Chronic Disease: A Discrete Choice Experiment.

Authors:  Yingying Peng; Mingzhu Jiang; Xiao Shen; Xianglin Li; Erping Jia; Juyang Xiong
Journal:  Patient Prefer Adherence       Date:  2020-09-17       Impact factor: 2.711

4.  Application of Prescription Reviews for Traditional Chinese Medicine to Improve Medical Disputes and Patient Satisfaction.

Authors:  Chunlan Yu; Shanmei Xu
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-07       Impact factor: 2.650

5.  Traditional chinese medicine zheng in the era of evidence-based medicine: a literature analysis.

Authors:  Miao Jiang; Chi Zhang; Guang Zheng; Hongtao Guo; Li Li; Jing Yang; Cheng Lu; Wei Jia; Aiping Lu
Journal:  Evid Based Complement Alternat Med       Date:  2012-06-06       Impact factor: 2.629

6.  Therapeutic Effects of Cortex acanthopanacis Aqueous Extract on Bone Metabolism of Ovariectomized Rats.

Authors:  Zhiguo Zhang; Jiazi Dong; Meijie Liu; Yan Li; Jinghua Pan; Hong Liu; Wenlai Wang; Dong Bai; Lihua Xiang; Gary G Xiao; Dahong Ju
Journal:  Evid Based Complement Alternat Med       Date:  2012-09-11       Impact factor: 2.629

7.  Chinese patent medicine liu wei di huang wan combined with antihypertensive drugs, a new integrative medicine therapy, for the treatment of essential hypertension: a systematic review of randomized controlled trials.

Authors:  Jie Wang; Kuiwu Yao; Xiaochen Yang; Wei Liu; Bo Feng; Jizheng Ma; Xinliang Du; Pengqian Wang; Xingjiang Xiong
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-11       Impact factor: 2.629

8.  Effect of combining therapy with traditional chinese medicine-based psychotherapy and herbal medicines in women with menopausal syndrome: a randomized controlled clinical trial.

Authors:  Hongyan Yang; Jing Yang; Zehuai Wen; Qinglin Zha; Guangning Nie; Xuchun Huang; Chunlin Zhang; Aiping Lu; Miao Jiang; Xiaoyun Wang
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-10       Impact factor: 2.629

9.  Tianma gouteng yin as adjunctive treatment for essential hypertension: a systematic review of randomized controlled trials.

Authors:  Jie Wang; Bo Feng; Xiaochen Yang; Wei Liu; Yongmei Liu; Yun Zhang; Gui Yu; Shengjie Li; Yuqing Zhang; Xingjiang Xiong
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-24       Impact factor: 2.629

10.  Integrating traditional chinese medicine services in community health centers: insights into utilization patterns in the pearl river region of china.

Authors:  Vincent C H Chung; Polly H X Ma; Harry H X Wang; Jia Ji Wang; Lau Chun Hong; Xiaolin Wei; Samuel Y S Wong; Jin Ling Tang; Sian M Griffiths
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-20       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.